Summary
During this RISE project we aim to develop nanoparticle-based encapsulated libraries of different immunotherapeutic
biomolecules for treatment after surgery as part of a novel cancer management strategy. The current state-of-art for the
management of cancer starts with surgery, after identification of an accessible tumour mass. Surgery remains an effective
treatment option for many types of cancer today and it is considered curative treatment for most solid tumours. It forms part
of a multidisciplinary approach used in conjunction with radiotherapy or chemotherapy. These approaches, however, have
several limitations, including inability of surgical resection to affect distal metastatic disease, toxicity to healthy tissues with
chemotherapy and lack of effectiveness of radiation therapy in more aggressive tumours. The observation that cancer can
relapse months or years after initial surgery implies that micrometastases still resides within the body in a latent state. Our
proposal is to take cancer therapy to beyond state-of-art by implementing techniques which will take us into new directions.
This includes a) new methods to identify immune gene profiles and biomarkers b) transgenic mouse models where the
complex interactions that underlie immune function can be visualised as multiplexed events in real time and c) the use of
nanoparticle-based libraries of immune modulating reagent combinations. There are three key objectives within this project:
i) to use immune gene signatures to monitor disease progression and therapeutic efficacy of immunotherapy combinations
on nanoparticle-based platforms, ii) to optimise the platform to encapsulate libraries of immune components for more
personalised, accurate and timely delivery of the payload to its intended target and iii) to optimise the overall cancer
management process of image-guided surgery followed by postoperative immunotherapy so that we can ultimately provide a
lifetime of protection against cancer.
biomolecules for treatment after surgery as part of a novel cancer management strategy. The current state-of-art for the
management of cancer starts with surgery, after identification of an accessible tumour mass. Surgery remains an effective
treatment option for many types of cancer today and it is considered curative treatment for most solid tumours. It forms part
of a multidisciplinary approach used in conjunction with radiotherapy or chemotherapy. These approaches, however, have
several limitations, including inability of surgical resection to affect distal metastatic disease, toxicity to healthy tissues with
chemotherapy and lack of effectiveness of radiation therapy in more aggressive tumours. The observation that cancer can
relapse months or years after initial surgery implies that micrometastases still resides within the body in a latent state. Our
proposal is to take cancer therapy to beyond state-of-art by implementing techniques which will take us into new directions.
This includes a) new methods to identify immune gene profiles and biomarkers b) transgenic mouse models where the
complex interactions that underlie immune function can be visualised as multiplexed events in real time and c) the use of
nanoparticle-based libraries of immune modulating reagent combinations. There are three key objectives within this project:
i) to use immune gene signatures to monitor disease progression and therapeutic efficacy of immunotherapy combinations
on nanoparticle-based platforms, ii) to optimise the platform to encapsulate libraries of immune components for more
personalised, accurate and timely delivery of the payload to its intended target and iii) to optimise the overall cancer
management process of image-guided surgery followed by postoperative immunotherapy so that we can ultimately provide a
lifetime of protection against cancer.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/777682 |
| Start date: | 01-03-2018 |
| End date: | 31-08-2023 |
| Total budget - Public funding: | 2 430 000,00 Euro - 2 430 000,00 Euro |
Cordis data
Original description
During this RISE project we aim to develop nanoparticle-based encapsulated libraries of different immunotherapeuticbiomolecules for treatment after surgery as part of a novel cancer management strategy. The current state-of-art for the
management of cancer starts with surgery, after identification of an accessible tumour mass. Surgery remains an effective
treatment option for many types of cancer today and it is considered curative treatment for most solid tumours. It forms part
of a multidisciplinary approach used in conjunction with radiotherapy or chemotherapy. These approaches, however, have
several limitations, including inability of surgical resection to affect distal metastatic disease, toxicity to healthy tissues with
chemotherapy and lack of effectiveness of radiation therapy in more aggressive tumours. The observation that cancer can
relapse months or years after initial surgery implies that micrometastases still resides within the body in a latent state. Our
proposal is to take cancer therapy to beyond state-of-art by implementing techniques which will take us into new directions.
This includes a) new methods to identify immune gene profiles and biomarkers b) transgenic mouse models where the
complex interactions that underlie immune function can be visualised as multiplexed events in real time and c) the use of
nanoparticle-based libraries of immune modulating reagent combinations. There are three key objectives within this project:
i) to use immune gene signatures to monitor disease progression and therapeutic efficacy of immunotherapy combinations
on nanoparticle-based platforms, ii) to optimise the platform to encapsulate libraries of immune components for more
personalised, accurate and timely delivery of the payload to its intended target and iii) to optimise the overall cancer
management process of image-guided surgery followed by postoperative immunotherapy so that we can ultimately provide a
lifetime of protection against cancer.
Status
SIGNEDCall topic
MSCA-RISE-2017Update Date
28-04-2024
Images
No images available.
Geographical location(s)
Search
Organisations
-
| PERCUROS BV (Coördinator)
-
| ACADEMISCH ZIEKENHUIS LEIDEN (LUMC)
-
| ASSOCIAZIONE CULTURALE CASTELLI ROMANI GREEN TOUR
-
| ASSOCIAZIONE HAND IN HAND
-
| AUGEAS ASSOCIAZIONE DI SPORT PROMOZIONE E TURISMO
-
| BOSCHIVA MELCHIORRI SRL
-
| ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
-
| HELRIK AND LOUW AND PARTNERS COMPANY LTD
-
| HELRIK AND LOUW COMPANY LTD
-
| JENACELL GMBH
-
| MEDRES-MEDICAL RESEARCH GMBH
-
| PROGREDUM GMBH
-
| TECHNISCHE UNIVERSITEIT DELFT
-
| TECOBIOSCIENCES GMBH
-
| THE UNIVERSITY OF SHEFFIELD